Investigational drug · Phase 2
FID007
Also called: Paclitaxel in Polyethyloxazoline Polymer, Nanoencapsulated Paclitaxel FID-007
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Head and Neck Squamous Cell Carcinoma.
Phase 2Last checked: Nov 19, 2026Latest source record: Oct 14, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
3
Any phase or sponsor naming "FID007"
First trial start
2024
Apr 10, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "FID007", any sponsor or status.
Conditions studied
As listed on its trial records.
- Head and Neck Squamous Cell Carcinoma
Approved drugs for the same conditions: Head and neck cancer · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "FID007" as an intervention, largest first.
- FID-007 in Treating Participants With Advanced Solid TumorsActive, not recruiting
University of Southern CaliforniaAcademic, hospital or other
NCT03537690 · 50 participants · Start May 25, 2018 · Primary completion Dec 31, 2026
Drug: PEOX-based Polymer Encapsulated Paclitaxel FID-007 · For: Advanced Malignant Solid Neoplasm; Refractory Malignant Solid Neoplasm
Sites: Los Angeles, California; Newport Beach, California · 3 sites in all
- FID-007 and Cetuximab in Treating Patients With Advanced Head and Neck Squamous Cell CarcinomaActive, not recruiting
Fulgent Pharma LLC.Industry
NCT06332092 · 46 participants (planned) · Start Apr 10, 2024 · Primary completion Dec 31, 2025
Drug: FID007 · For: Head and Neck Squamous Cell Carcinoma
Sites: Fayetteville, Arkansas; Los Angeles, California; Tampa, Florida · 6 sites in all
University of Southern CaliforniaAcademic, hospital or other
NCT06338657 · 1 participants · Start Apr 1, 2024 · Primary completion Sep 3, 2025
Drug: PEOX-based Polymer Encapsulated Paclitaxel FID-007 · For: Head and Neck Squamous Cell Carcinoma
Sites: Los Angeles, California · 2 sites in all
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Head and Neck Squamous Cell Carcinoma
- BMS-986507BL-B01D1, Iza-brenPhase 351 trials
Sichuan Baili Pharmaceutical Co., Ltd. · Non-small Cell Lung Cancer, Solid Tumor, Urothelial Carcinoma
- HS-20093Ris-Rez, Risvutatug rezetecanPhase 316 trials
Hansoh BioMedical R&D Company · Neoplasms, Lung, Sarcoma, Osteosarcoma
- Telisotuzumab AdizutecanABBV-400Phase 316 trials
AbbVie · c-MET, Non-Squamous Non-Small Cell Lung Cancer, Metastatic Colorectal Cancer
- SG001enlonstobart, Enlonstobart will be administrated on a 14-day cyclePhase 315 trials
CSPC Megalith Biopharmaceutical Co.,Ltd. · HER2-positive Gastric Cancer, Esophageal Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma
- SYS6010Phase 315 trials
CSPC Megalith Biopharmaceutical Co.,Ltd. · Non-Small Cell Lung Cancer, Esophageal Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma
- AK117Phase 314 trials
Akeso · Advanced Malignant Tumors, ACUTE MYELOID LEUKEMIA; AML, Higher-risk Myelodysplastic Syndromes
- FianlimabREGN3767Phase 311 trials
Regeneron · Melanoma, Non-small Cell Lung Cancer, Hepatocellular Carcinoma
- ZanzalintinibXL092Phase 311 trials
Exelixis · Colorectal Cancer, Renal Cell Carcinoma, Head and Neck Squamous Cell Carcinoma
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.